Report Library
All Reports
HCV KOL Insight Interview and Pulse Survey Bundle
December 11, 2013
BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2013-
2014 for purchase a la carte, or access to all reports and surveys can be purchased as a
subscription to KOL Insight. For more information on KOL Insight subscription, please
email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
The recent approvals of Sovaldi (sofosbuvir) and Olysio (simeprevir) have spurred debate regarding patient use of combinations, both labelled and off-label for the treatment of HCV in 2014 and beyond. We conducted an in-depth interview of a Knowledge and Opinion Leader following AASLD and we surveyed 30 US hepatologists regarding their expectations for the HCV treatment landscape over the next few years.
KOL Highlights Include:
For our disclosures, please read the BioMedTracker Research Standards.
The recent approvals of Sovaldi (sofosbuvir) and Olysio (simeprevir) have spurred debate regarding patient use of combinations, both labelled and off-label for the treatment of HCV in 2014 and beyond. We conducted an in-depth interview of a Knowledge and Opinion Leader following AASLD and we surveyed 30 US hepatologists regarding their expectations for the HCV treatment landscape over the next few years.
KOL Highlights Include:
- Sofosbuvir-based therapies will be the regimens-of-choice for the treatment of Hepatitis C
- LONESTAR presentation showing patient response with more potent regimen, shows that effective retreatment is possible with sofosbuvir-based regimens
- GT2/3, post-transplant patients, and HIV co-infected will be treated ASAP with sofosbuvir- based regimens
- Upcoming approvals will likely lead to off-label use of interferon-free regimens in cirrhotic GT1 patients with Phase II data supporting sofosbuvir/simeprevir (COSMOS) or sofosbuvir/ribavirin for 24 weeks (SPARE)
- Approval of sofosbuvir/ledipasvir FDA and ABBV regimen in 2015 will open the flood gates to include F0-F2 GT1 patients; ABBV will need to compete with pricing as physicians will be comfortable with sofosbuvir-based regimens
- Merck’s regimen MK-5172/MK-8742 looks effective but may be too late, with approval expected in 2017, as 2015 marks the beginning of the “end-game”
For our disclosures, please read the BioMedTracker Research Standards.
| Disease Group Covered: |
Gastroenterology (Non Inflammatory Bowel Disease)
Infectious Disease |
Additional Resources: